Avadel Pharmaceuticals plc (NASDAQ: AVDL) is -22.73% lower on its value in year-to-date trading and has touched a low of $10.39 and a high of $19.09 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AVDL stock was last observed hovering at around $11.59 in the last trading session, with the day’s loss setting it -0.68%.
Currently trading at $10.91, the stock is -20.96% and -19.10% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.08 million and changing -5.87% at the moment leaves the stock -28.37% off its SMA200. AVDL registered -0.09% loss for a year compared to 6-month loss of -29.57%. The firm has a 50-day simple moving average (SMA 50) of $13.4856 and a 200-day simple moving average (SMA200) of $15.2308.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -21.62% gain in the last 1 month and extending the period to 3 months gives it a -32.45%, and is -31.56% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.74% over the week and 6.01% over the month.
Avadel Pharmaceuticals plc (AVDL) has around 154 employees, a market worth around $1.05B and $138.16M in sales. Fwd P/E is 20.11. Profit margin for the company is -52.53%. Distance from 52-week low is 5.00% and -42.85% from its 52-week high. The company has generated returns on investments over the last 12 months (-65.79%).
with sales reaching $53.07M over the same period.The EPS is expected to grow by 76.06% this year, but quarterly earnings will post 515.08% year-over-year. Quarterly sales are estimated to grow 172.80% in year-over-year returns.
Avadel Pharmaceuticals plc (AVDL) Top Institutional Holders
231.0 institutions hold shares in Avadel Pharmaceuticals plc (AVDL), with institutional investors hold 84.07% of the company’s shares. The shares outstanding are 89.83M, and float is at 87.75M with Short Float at 10.77%. Institutions hold 80.06% of the Float.
The top institutional shareholder in the company is VIVO CAPITAL, LLC with over 3.97 million shares valued at $55.85 million. The investor’s holdings represent 4.332% of the AVDL Shares outstanding. As of 2024-06-30, the second largest holder is TRI LOCUM PARTNERS LP with 1.19 million shares valued at $16.72 million to account for 1.2973 of the shares outstanding. The other top investors are BIOIMPACT CAPITAL LLC which holds 0.78 million shares representing 0.8542% and valued at over $11.01 million, while KNOLL CAPITAL MANAGEMENT, LLC holds 0.6544 of the shares totaling 0.6 million with a market value of $8.44 million.
Avadel Pharmaceuticals plc (AVDL) Insider Activity
The most recent transaction is an insider purchase by MCHUGH THOMAS S, the company’s Chief Financial Officer. SEC filings show that MCHUGH THOMAS S bought 2,000 shares of the company’s common stock on Jan 16 ’24 at a price of $14.50 per share for a total of $29000.0. Following the purchase, the insider now owns 80500.0 shares.
Avadel Pharmaceuticals plc disclosed in a document filed with the SEC on Dec 28 ’23 that McCamish Mark Anthony (Director) sold a total of 75,000 shares of the company’s common stock. The trade occurred on Dec 28 ’23 and was made at $14.53 per share for $1.09 million. Following the transaction, the insider now directly holds 67025.0 shares of the AVDL stock.
